Clinical trials: Prostate Disease
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Overactive Bladder
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
- Trial name
- NCT01220726
- Testing
- Botox
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.
- Trial name
- NCT01386684
- Volunteers
- 552 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Prostate Cancer
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: Docetaxel (a type of chemotherapy) Apalutamide (the study…
- Trial name
- NCT03093272
- Testing
- Leuprolide Acetate, Prednisone, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).
- Trial name
- NCT00577356
- Testing
- Docetaxel, CG1940/CG8711
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Benaroya Research Institute
Enlarged Prostate
3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization
The purpose of this research study is to learn about how cone-beam Computerized Tomography scans (X-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries…
- Trial name
- NCT03164629
- Testing
- cone-beam CT 3D Emboguide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Prostate Cancer
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Background: No treatment is known to improve survival for prostate cancer patients who have not been helped by previous treatments with hormones and chemotherapy.
- Trial name
- NCT00450619
- Testing
- Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Neoplasms, Prostate
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
- Trial name
- NCT00363311
- Testing
- Dutasteride
- Where
- 82 sites in United States, Canada
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has…
- Trial name
- NCT04422132
- Testing
- 5 days Radiation Therapy (32.5 Gy in 5 fractions), 20 days Radiation therapy (55 Gy in 20 fractions)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer, Erectile Dysfunction
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
Radiation sometimes affects the ability for a person to have a normal erection. Complete loss of erections after radiation treatment can happen in 40-50% of treated patients.
- Trial name
- NCT00142506
- Testing
- sildenafil citrate and questionaires
- Where
- 5 sites in United States
- Volunteers
- 290 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Sexual Dysfunction
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy.
- Trial name
- NCT00931528
- Testing
- Tadalafil
- Where
- 192 sites in United States, Canada
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients
This study will examine the utility of chitosan for reduction of blood or tissue levels of AGEs in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.
- Trial name
- NCT03712371
- Testing
- Chitosan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
FACBC Prostate Therapy Response
The purpose of this study is to assess if using anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment.
- Trial name
- NCT02830880
- Testing
- FACBC PET-CT, MRI, CT, or Bone Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Prostate Cancer
Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00499694
- Testing
- bevacizumab, satraplatin
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostatic Neoplasms
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
This is a multicentered, open label, randomized phase II trial of PROSTVAC or ipilimumab or the combination of PROSTVAC and ipilimumab as neoadjuvant therapy in patients with localized prostate cancer.
- Trial name
- NCT02506114
- Testing
- PROSTVAC V/F, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lawrence Fong
Prostate Cancer, Penile Diseases
Penile Length Maintenance Post-Prostatectomy
The objective of the current study is to evaluate the efficacy of a novel, class I (ie. lowest risk, clinical studies not required) medical penile traction device in preventing loss of penile length in men undergoing…
- Trial name
- NCT03500419
- Testing
- RestoreX, No treatment
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Vitamin D Deficiency
Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans
Veterans between the ages of 50-75, who are having a prostate biopsy, will be recruited for their permission to collect an extra biopsy core for RNA-sequencing.
- Conditions
- Prostate Cancer, Vitamin D Deficiency, Stress Reaction
- Trial name
- VitD/RNA-seq (NCT04621500)
- Testing
- cholecalciferol, Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq, Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Benign Prostatic Hyperplasia
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
- Trial name
- NCT03297398
- Testing
- Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004)
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- OPKO Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.